Description: Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.
Home Page: www.passagebio.com
PASG Technical Analysis
One Commerce Square
Philadelphia,
PA
19103
United States
Phone:
267 866 0311
Officers
| Name | Title |
|---|---|
| Dr. William Chou M.D. | CEO & Director |
| Dr. James M. Wilson M.D., Ph.D. | Co-Founder & Chief Scientific Advisor |
| Ms. Simona King | CFO & Corp. Sec. |
| Mr. Alexandros Fotopoulos MBA, MSc | Chief Technical Officer |
| Mr. Stuart M. Henderson | VP of Corp. Devel. & Investor Relations |
| Mr. Edgar B. Cale Esq., J.D. | Gen. Counsel & Company Sec. |
| Gregory Fuest | VP of Global Commercial Strategy & Marketing |
| Dr. Mark Forman M.D., Ph.D. | Chief Medical Officer |
| Desiree Luthman D.D.S. | Sr. VP of Global Regulatory Affairs |
| David Weinstein M.D. | Sr. VP of Clinical Devel. |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.3039 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2020-02-28 |
| Fiscal Year End: | December |
| Full Time Employees: | 133 |